High expression of PDGFR-β is an indicator of poor prognosis, and high expression of c-MET may predict therapeutic effectiveness of sorafenib treatment, allowing individualized treatment of HCC patients. The gene discussed is PDGFRB; the disease is hepatocellular carcinoma.